Bharat Parenterals Ltd. · BSE:BPLPHARMA
Bharat Parenterals — Q1 FY2026 Earnings Presentation
26 slides from Bharat Parenterals's earnings presentation, Jul 28, 2025
Slide 1: Investor presentation filing letter to BSE
Date: 28.07.2025 To, Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001. Script Code: 541096 Dear Sir/Madam, Subject: Investor Presentation for the quarter ended June 30, 2025. Pursuant to Regulation 30 of the SEBI (Listin
Slide 2: Bharat Parenterals Limited July 2025
Bharat Parenterals Limited JULY 2025
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “pl
Slide 4: Table of contents
Table of contents 1 Market overview 4-7 2 Group overview 8 – 20 3 Financial update 21 - 25 3
Slide 5: Market overview
Market overview 4
Slide 6: Global medicine spending to reach $2.4 trillion by 2029
Global medicine spending to reach $ 2.4 trillion by 2029f with a few key themes having the greatest impact on growth and profitability Global medicine market spending 1 Key themes in the generic finished dosage formulations space 2,800 1 GEOGRAPHY • High volume growth and negligible price erosion in
Slide 7: Emerging markets expected to experience high growth in spending and volume
Emerging markets expected to experience high growth in spending and volume, while both volume and spending growth to be muted in the developed markets 1 Population driven volumes and shift towards more expensive medicines because of improved healthcare penetration and rising per capital income will
Slide 8: Branded generics and specialty medicines most rewarding spaces
Branded generics in emerging markets and specialty medicines in developed markets expected to be the most rewarding spaces 2 Specialty medicines will be one of the most rewarding spaces in developed 3 The branded generics segment will be the most attractive in Pharmerging markets as the share of spe
Slide 9: Group overview
Group overview 8
Slide 10: The BPL group is built to develop and manufacture FDFs for global markets
The BPL group is built to develop and manufacture FDFs for global markets… Group overview Bharat Parenterals Pvt. Ltd. (listed holding company) Particulars Details Focus: Export-led pharmaceutical manufacturer of finished Standalone dosage forms (FDFs). Location Vadodara, Gujarat Key therapies: Anti
Slide 11: Key milestones
The BPL group is built to develop and manufacture FDFs for global markets… Key milestones Incorporation Commenced exports Varenyam Bio Bharat Parenterals BPL commenced Established Established Innoxel Innoxel Lifesciences Lifesciences and Ltd. (“BPL") exporting to Varenyam Lifesciences becomes Vareny
Slide 12: Poised to achieve rapid revenue growth and margin expansion
…Poised to achieve rapid revenue growth and margin expansion over the next few years… 1 Deep entrenchment in high-growth geographies enabled by experience of 3+ decades Bharat Parenterals Solid core business primed for growth and Regularly upgraded manufacturing facility through the decade margin ex
Slide 13: Product registration pipeline aims to diversify geography mix
1 Regulatorily accredited manufacturing infrastructure Product registration pipeline aims to diversify geography mix Diversification to achieve growth and margin expansion First-time filings in new countries to New product filings in select existing • Enhanced focus on APAC and LATAM that have highe
Slide 14: Therapy area focus and product mix
1 …Therapy area focus, and product mix Sound strategy guiding therapy area-wise objectives Therapy area Thoughtfully designed product registration pipeline Strategy Current Future • Anti-infectives are competitive spaces with moderate margins • BPL has selectively filed newer classes of antibiotics
Slide 15: Innoxel at a glance
2 Innoxel at a glance Innoxel is an innovation-driven, regulated market CDMO with their own product portfolio of specialty generics Snapshot Business segments Infrastructure • Overview: Located in Vadodara with a total manufacturing area of 350,000 Portfolio of own products which have been out- ➢ In
Slide 16: Innoxel business segment overview
2 Business segment overview Innoxel has two business segments with revenues from manufacturing, milestone achievements, and profit share from clients and partners Segments Own products CMO • Innoxel identifies and carries out product development up to a certain stage, • Innoxel manufactures the prod
Slide 17: Founding team with the perfect blend of skills
2 Founding team with the perfect blend of skills to build a regulated market CDMO success story Pillars of a regulated market CDMO success story Robust regulatory & Operational excellence Differentiated R&D skills Sound strategic direction Wide clinical experience Deep commercial networks compliance
Slide 18: Ability to formulate solutions for unmet healthcare needs
2 …With the ability to formulate solutions for unmet healthcare needs… Category Drug characteristics Impact • The encapsulated drug is protected from rapid degradation and elimination by the body • The drug circulates in the body for longer, allowing for modified drug release profiles (sustained/con
Slide 19: Well-hedged against all types of risk across the CDMO continuum
2 Well-hedged against all types of risk through leverage of strengths across the CDMO continuum Risks Description Innoxel’s hedge • Inability to successfully complete formulation • Dr. Manish has led the development of over half the currently marketed liposomal injectables Development risk developme
Slide 20: Varenyam Healthcare: speciality branded generics business
3 Varenyam Healthcare is a high-impact speciality branded generics business. Overview Established in 2016, Varenyam Healthcare is a specialty pharmaceutical company focused on critical care, anesthesia, and pain management. Presence in 7,500+ hospitals across India, supported by a 180+ person field
Slide 21: Varenyam Bio leverages Innoxel's portfolio and BPL's market access
4 Varenyam Bio leverages Innoxel’s complex product portfolio & BPL’s market access to further expand the group PRODUCT PORTFOLIO Leverages Innoxel’s & BPL’s R&D pipeline through in- licensing, reducing time-to-market and avoiding repeat development. Focused on complex dosage forms (injectables, long
Slide 22: Financial update
Financial update 21
Slide 23: Financial metrics | Standalone
Financial metrics | Standalone Total operating revenue (INR crore) EBITDA (INR crore and as %) PAT (INR crore and as %) 10.00% 10.00% 8.89% 8.70% 16.33% 13.75% 10.43% 11.49% 11.04% 9.98% 26 24 34 21 23 304 29 29 254 21 212 218 15 10 94 FY 2022 FY 2023 FY 2024 FY 2025 Q1FY26 FY 2022 FY 2023 FY 2024 F
Slide 24: Standalone key financials Q1 FY26
Financial metrics | Standalone key financials Q1 FY 26 Figures in INR crore Particulars Q1 FY 2026 Q1 FY 2025 Change (%) FY 2025 FY 2024 Change (%) Revenue from operations 94.37 92.06 +2.51% 304.13 257.98 +17.89% Other operating revenue 1.47 3.90 14.55 8.04 Total operating revenue 95.84 95.96 -0.13%
Slide 25: Financial metrics | Consolidated
Financial metrics | Consolidated Total operating revenue (INR crore) EBITDA (INR crore and as %) PAT (INR crore and as %) 13.52% 11.90% 9.56% 9.31% 11.94% 6.97% 24 21 3.88% 19 (12.4%) 16 (0.73%) 0.79% 14 340 29 11 23 257 20 9 212 218 14 (44) 116 4 3 (1) FY 2022 FY 2023 FY 2024 FY 2025 Q1FY26 (1) FY
Slide 26: Consolidated key financials Q1 FY26
Financial metrics | Consolidated key financials Q1 FY 26 Figures in INR crore Particulars Q1 FY 2026 Q1 FY 2025 Change (%) FY 2025 FY 2024 Change (%) Revenue from operations 116.00 92.51 +25.4% 340.38 261.22 +30.3% Other operating revenue 1.06 2.54 11.90 4.68 Total operating revenue 117.06 95.05 +23